417 related articles for article (PubMed ID: 25035968)
1. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
[TBL] [Abstract][Full Text] [Related]
2. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.
Dekempeneer Y; Keyaerts M; Krasniqi A; Puttemans J; Muyldermans S; Lahoutte T; D'huyvetter M; Devoogdt N
Expert Opin Biol Ther; 2016 Aug; 16(8):1035-47. PubMed ID: 27145158
[TBL] [Abstract][Full Text] [Related]
3. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview.
Sharma R; Suman SK; Mukherjee A
Curr Med Chem; 2022; 29(38):5979-6005. PubMed ID: 35674298
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy.
Piramoon M; Khodadust F; Hosseinimehr SJ
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188529. PubMed ID: 33647388
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies in cancer.
Verhaar ER; Woodham AW; Ploegh HL
Semin Immunol; 2021 Feb; 52():101425. PubMed ID: 33272897
[TBL] [Abstract][Full Text] [Related]
7. Current status and future expectations of nanobodies in oncology trials.
De Pauw T; De Mey L; Debacker JM; Raes G; Van Ginderachter JA; De Groof TWM; Devoogdt N
Expert Opin Investig Drugs; 2023; 32(8):705-721. PubMed ID: 37638538
[TBL] [Abstract][Full Text] [Related]
8. Targeted radionuclide therapy: frontiers in theranostics.
Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
[TBL] [Abstract][Full Text] [Related]
9. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
10. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
Al-Baradie RS
Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
[TBL] [Abstract][Full Text] [Related]
11.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
12. Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer.
Van Audenhove I; Gettemans J
EBioMedicine; 2016 Jun; 8():40-48. PubMed ID: 27428417
[TBL] [Abstract][Full Text] [Related]
13. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.
Hrynchak I; Santos L; Falcão A; Gomes CM; Abrunhosa AJ
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639086
[TBL] [Abstract][Full Text] [Related]
14. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
Front Immunol; 2021; 12():838082. PubMed ID: 35116045
[TBL] [Abstract][Full Text] [Related]
15. Multifunctional radiolabeled nanoparticles: strategies and novel classification of radiopharmaceuticals for cancer treatment.
Enrique MA; Mariana OR; Mirshojaei SF; Ahmadi A
J Drug Target; 2015 Apr; 23(3):191-201. PubMed ID: 25534010
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
[TBL] [Abstract][Full Text] [Related]
17. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Naidoo DB; Chuturgoon AA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
[TBL] [Abstract][Full Text] [Related]
19. Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q; De Vlaeminck Y; Hanssens H; D'Huyvetter M; Raes G; Goyvaerts C; Keyaerts M; Devoogdt N; Breckpot K
Theranostics; 2019; 9(25):7772-7791. PubMed ID: 31695800
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]